ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Emergent Biosolutions Inc

Emergent Biosolutions Inc (EBS)

1.52
-0.04
(-2.56%)
Closed February 20 04:00PM
1.55
0.03
(1.97%)
After Hours: 07:10PM

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

EBS News

Press Releases Only

EBS Discussion

View Posts
allenc allenc 2 weeks ago
Lets see what happens when the financials are released. If they hit their sales target with the OTC Narcan, should be nice net profits, JMO
👍️0
Monksdream Monksdream 2 weeks ago
EBS new 52 week low
👍️0
allenc allenc 3 weeks ago
What is up with this company? Management gonna ride this into the ground and bury it?
👍️0
Monksdream Monksdream 1 month ago
EBS new 52 week low
👍️0
Monksdream Monksdream 3 months ago
EBS new 52 week low
👍️0
Monksdream Monksdream 4 months ago
EBS new 52 week low
👍️0
Biggiee Biggiee 4 months ago
Heaping pile of company. Haven’t seen this kind of incompetence in all my years of trading! Narcan everywhere! And this company is collapsing!
👍️0
Monksdream Monksdream 5 months ago
EBS new 52 week low
👍️0
Monksdream Monksdream 5 months ago
EBS new 52 week low
👍️0
Biggiee Biggiee 5 months ago
I’m starting to shift opinions on this… might be a turd of a company. There has to be something seriously rotten here for SP to plummet through 52 week lows.
GL
👍️0
Biggiee Biggiee 5 months ago
This has not gone the way it should.
Hmmm….
👍️0
Biggiee Biggiee 6 months ago
I’m sure a lot of competitors will try, but Narcan is proven, trusted and ahead of all of them. If this was a race, the $EBS horse is waaaay ahead. I’ve learned to stay clear from really long shot ideas that required a lot a praying. IMO, this is the horse to bet on, especially so near 52 week lows.
GL
👍️0
Piola Piola 6 months ago
Hi;
I’m long for EBS. I think it has great potential.
I just have a question. I’ve read that RiVive will come up with its own nasal narcan. Will this have significant impact on EBS?
Doc
👍️0
Biggiee Biggiee 6 months ago
18% short interest. This could run big into September when Narcan shows up in stores and gets local/national news
GL $EBS
👍️0
Biggiee Biggiee 6 months ago
Narcan for everybody!! $EBS
👍️0
TheFinalCD TheFinalCD 7 months ago
https://ih.advfn.com/stock-market/NYSE/emergent-biosolutions-EBS/stock-news/91689294/emergent-biosolutions-awarded-10-year-barda-contra

almost exactly 1 year later
👍️0
LearningEveryTrade LearningEveryTrade 2 years ago
Cali State of Emergency https://www.gov.ca.gov/2022/08/01/74502/
👍️0
Elgordo84 Elgordo84 2 years ago
Looks like this sleeping Giant
Is getting ready to awake!
Let’s go $EBS
👍️0
InkynClyde InkynClyde 2 years ago
Building position
👍️0
Cuppy Cuppy 3 years ago
"Emergent was forced to halt operations at its plant in the Bayview area of Baltimore after contamination issues led to millions of spoiled vaccine doses."

https://www.nytimes.com/2021/06/16/us/emergent-biosolutions-covid-vaccine.html?action=click&module=Top%20Stories&pgtype=Homepage

since your recommendation, it has lost half its value.
👍️0
T695 T695 3 years ago
Buy buy buy
👍️0
T695 T695 3 years ago
One patient got sick out of 60,000.
Buy buy buy
👍️0
T695 T695 3 years ago
Gift
👍️0
GoSlowDudes GoSlowDudes 3 years ago
EPS

2019 $2.88
2020 $6.59
2021 $7.96

P/E = 14.70 on next years earnings. Cheap stock compared to S &P which is in the mid 20’s depending on which one you use.
👍️0
Hitman970 Hitman970 4 years ago
Cannon! Bull Flag Alert!!!!
👍️0
TREND1 TREND1 4 years ago


Emergent BioSolutions Signs Development and Manufacturing Agreement with Vaxart for their Experimental Oral Vaccine Candidate for Coronavirus Disease



GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company, whereby Emergent has agreed to utilize its molecule-to-market contract development and manufacturing (CDMO) services to develop and manufacture Vaxart’s experimental oral vaccine candidate for coronavirus disease (COVID-19). Development services will begin immediately, and upon Vaxart’s election, Emergent agrees to produce clinical material expected to enable Vaxart to initiate a Phase 1 clinical study anticipated early in the second half of 2020. Vaxart’s oral recombinant vaccine candidate is based on its proprietary VAAST™ platform.

“Emergent is pleased to deploy our nimble CDMO expertise to support fellow innovators, like Vaxart, and advance an experimental COVID-19 vaccine candidate,” said Syed T. Husain, senior vice president and CDMO business unit head at Emergent BioSolutions. “We look forward to applying our broad molecule-to-market services, including our ability to work with a multitude of delivery systems, execute under expedited timelines, and meet Vaxart’s potential need for future scalability and large-scale capacity for commercial quantities.”
Under the terms of the agreement, Emergent will provide development services out of its Gaithersburg, Md. location and manufacture drug substance at its Bayview facility in Baltimore, Md., designated a Center for Innovation in Advanced Development and Manufacturing (CIADM) by the U.S. Department of Health and Human Services. Emergent’s Bayview CIADM is the same facility used to manufacture drug substance for the company’s recently announced Novavax collaboration. The facility has the capacity to produce tens to hundreds of millions of doses of vaccine on an annual basis, based upon the platform technology being leveraged. Additionally, it has the unique capability of producing at clinical scale, to get vaccine candidates quickly into the clinic, and in parallel, scaling up to produce commercial volumes to meet customer demand.

“I’m pleased that we are joining forces with an experienced manufacturer such as Emergent to help advance our oral COVID-19 vaccine to the clinic,” said Wouter Latour, MD, chief executive officer of Vaxart. “We believe an oral vaccine administered using a room temperature-stable tablet may offer enormous logistical advantages in the roll-out of a large vaccination campaign, and Emergent is a great partner to help in this endeavor.”

About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our ability to advance potential solutions to combat coronavirus disease as well as the anticipated production level and use of the COVID-19 experimental vaccine candidate in a Phase 1 clinical study in the expected timeframe, are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.
statements.

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com

Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
KiefferL@ebsi.com


👍️0
GM26 GM26 4 years ago
Don’t have the actual contract, but here’s the link to the PR >> https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-development-and-manufacturing-0
👍️0
TREND1 TREND1 4 years ago
……………………....EPS
Mar 2020 04/30/2020 0.01
Dec 2019 02/20/2020 1.57
Sep 2019 11/06/2019 1.21
Jun 2019 08/01/2019 0.12
👍️0
TREND1 TREND1 4 years ago
EBS CHART


👍️0
TREND1 TREND1 4 years ago
Does any one know details of VXRT contract ?
👍️0
TREND1 TREND1 4 years ago
PE Ratio = 76

👍️0
TREND1 TREND1 4 years ago
EPS =1.03
👍️0
TREND1 TREND1 4 years ago
Revenue = $ 1.11B
👍️0
TREND1 TREND1 4 years ago
Market Cap=4.89 B

👍️0
GM26 GM26 4 years ago
Yeah I’m not sure why it’s acting this way. Should go back up once news is out on JNJ study on Vaxart oral pill soon.
👍️0
BTCDreamer BTCDreamer 4 years ago
And we know how well they're doing today! :)
👍️0
mick mick 4 years ago
Emergent Biosolution (EBS)
88.45 ? 4.37 (5.20%)
Volume: 272,203 @07/06/20 11:52:45 AM EDT
Bid Ask Day's Range
- - 84.75 - 88.63
EBS Detailed Quote
👍️0
GM26 GM26 4 years ago
And $VXRT ;)
👍️0
mick mick 4 years ago
PARTNER WIT $NVAX, $EBS
👍️0
grow fast grow fast 7 years ago
VistaTrades issued a BUY signal for EBS on 4.17.17
👍️0
stocktrademan stocktrademan 8 years ago
EBS bullish 28.88

stochastics crossing up out of oversold

market overreacted to light vaccine order and may have misinterpreted
http://www.investors.com/news/technology/emergent-biosolutions-stock-plunges-on-light-anthrax-vaccine-order/?ven=YahooCP&src=AURLLED&ven=yahoo

stock usually recovers from these types of dips
low risk high reward chart


👍️0
Bluesummers Bluesummers 8 years ago
An amazing company (would love to work for them some day).

Check out the Robinhood app (good for Android or IOS).

You can trade this company using that app for free.

Great way to start trading if you're new to the stock market (IMHO).
👍️0
$Pistol Pete$ $Pistol Pete$ 8 years ago
$EBS Daily and Weekly Charts



👍️0
$Pistol Pete$ $Pistol Pete$ 8 years ago
$EBS Daily Chart



👍️0
phryne phryne 9 years ago
I'd like to know how you checked his holdings out? I tried and failed.
👍️0
ShinSekai ShinSekai 9 years ago
I think I'm on to something huge. Check out Dr. Robin Robinson's recent dealings to get ahead of the curve. Their are a few more stocks poised to run up. Unfortunately a lot of the others are private. This stock, however, is one of the few that are public. Higher Monday for sure. :) I may retire before I'm 30
👍️0
ShinSekai ShinSekai 9 years ago
Yeah... I should've written hint hint wink wink. EBS was listed as an emergency facility in a government proposal by Dr. Robin Robinson. After some DD I figured it was only a matter of time. I hope this goes up Monday
👍️0
Contenders Contenders 9 years ago
EBS in the news today.

Looking forward to the action next week.

http://news.yahoo.com/exclusive-u-requests-production-plans-ebola-drug-zmapp-183307513--finance.html
👍️0
ShinSekai ShinSekai 9 years ago
We could sure use an Ebola vaccine contender.
👍️0
surf1944 surf1944 11 years ago
7:15AM Emergent BioSolutions BioSolutions announces 'positive' preclinical efficacy and PK Data for its new bispecific adaptir protein therapeutic ES414 at AACR; Treatment with ES414 showed statistically significant inhibition (EBS) 13.76 : The ES414 molecule was constructed using Emergent's ADAPTIR technology platform and selectively binds to the T cell receptor on cytotoxic T cells and Prostate Specific Membrane Antigen (PSMA), an antigen commonly found on prostate cancer cells.

Co announced the first poster, Emergent scientists described the efficacy of ES414 to prevent growth of human prostate cancer cells in vivo that express the PSMA protein on their surface: "Anti-PSMA x anti-CD3 ADAPTIR molecule inhibits tumor growth in vivo" Treatment with ES414 showed statistically significant inhibition of subcutaneous tumor outgrowth in the presence of human T cells in two independent mouse xenograft models of prostate cancer (C4-2B, MDA-PCa-2b). In both models, all treatment groups also showed a statistically significant decrease in serum PSA compared to negative controls.

Co announced The second poster described initial PK and tolerability: "Pharmacokinetic evaluation and tolerability assessment of anti-PSMA x anti-CD3 ADAPTIR molecule" These non-clinical studies showed that ES414 is pharmacologically active, has an extended serum half-life compared to antibody fragments, is well tolerated at levels well above the expected human dose, and possesses suitable characteristics for further in vivo toxicology studies.
👍️0

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com